Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Excilor is an over-the-counter topical treatment designed for the management of fungal nail infections (onychomycosis). Developed by Oystershell Laboratories and marketed by Vemedia (part of Cooper Consumer Health), the product is classified as a medical device rather than a pharmacological drug. Its primary mechanism of action is the acidification of the nail microenvironment; by utilizing acetic acid to lower the pH level within the nail plate, it creates a hostile environment that inhibits the growth and proliferation of dermatophytes. The formulation incorporates TransActive or TransActive+ Technology, which facilitates deep penetration of the active ingredients through the dense keratin of the nail without the need for filing. Excilor is available in several formats, including a solution and film-forming versions (Ultra and Forte) that provide sustained delivery of the treatment for up to 24 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Excilor.